Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. has announced the approval of Mimeixin, a novel pain management drug, by China’s NMPA for the treatment of severe pain in adults, highlighting its dual benefits of effective pain relief and reduced opioid-induced constipation. Mimeixin, which combines oxycodone and naloxone, is the first of its kind locally developed in China and incorporates drug-locking technology to curb abuse. The company anticipates significant market potential for Mimeixin, complementing its existing oncology product portfolio.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
